Diamedica Therapeutics Inc. · NASDAQ:DMAC

Diamedica Therapeutics — Technical Presentation (November 2023)

6 slides from Diamedica Therapeutics's technical presentation, Nov 13, 2023

  1. Slide 1: ReMEDy2 Updates

    ReMEDy2 Updates November 13, 2023

  2. Slide 2: Summary of ReMEDy2 Trial Protocol Key Changes

    Summary of ReMEDy2 Trial Protocol Key Changes Inclusion Criteria Guided by Recent Insights from KOLs & the Marketer of Urinary KLK1 in China * Changes iteria aimed, success: - for rationale) = Excluded posterior circulation strokes (see slide 6 for rationale) * Eliminate the option to stop ~ Provide

  3. Slide 3: Change to ReMEDy2 Clinical Trial Interim Analysis Plan

    Change to ReMEDy?2 Clinical Trial Interim Analysis Plan Eliminating op stopping for whelming Hiesey athe interim analy: but adaptive design rk rer in place 144 Participants Adaptive dese Options: 4-6 Months After Last Participant Enrolled Rationale Reduce statistical alpha penalty Larger safety data

  4. Slide 4: Excluding Baseline NIHSS 16-25 Participants

    Potential Benefit Of Excluding Baseline NIHSS 16-25 Participants ~3% Absolute/18% Relative Increase in mRS 0-1 in ReMEDy1 Phase 2 Post Hoc Analysis Primary Endpoint Improvement Excl. 16-25 = All Participants ao Mi Plcebo eas : Bo, Mom increase | 18 ~ 15% = +39% 3 2 é Relative | (18-15%) - +1996" x”

  5. Slide 5: Adding NIHSS 5 to the ReMEDy2 Study

    Potential Benefit of Adding NIHSS 5 to the REMEDy2 Study torue Poo! of Eligible Patients with NIHSS 5 with Potential to Improve Performance vs. Placebo -10 in the ReMEDy1 hms 0-3 at 90 Day NIH Placebo 1 i = Large % of ead 1 J Greatest ‘|NIHSS 5 ——— P23 8 tox MoM» ' con mee 8 1 || seen in NIHSS expec

  6. Slide 6: Excluding Posterior Circulation Strokes (PCS)

    Potential Benefit of Excluding Posterior Circulation Strokes (PCS) Consistent with Urinary KLK1 Inclusion/Exclusion Criteria of KLK1 Studies in China ), associated with the posterior circulation* * Additional z it 45, . i é i lng Bes! + Importantly, PCS ie Chi RESK study (1 Additional For Excluding

DiaMedica Therapeutics — Technical Presentation (November 2023) on 6ix